ASP5878

Catalog No.S6539 Batch:S653901

Print

Technical Data

Formula

C18H19F2N5O4
Molecular Weight 407.37 CAS No. 1453208-66-6
Solubility (25°C)* In vitro DMSO 81 mg/mL (198.83 mM)
Ethanol 4 mg/mL (9.81 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ASP5878 is a novel FGFR-selective inhibitor with IC50 values of 0.47, 0.60, 0.74, and 3.5 nmol/L for recombinant FGFR1, 2, 3, and 4, respectively.
Targets
FGFR1 [1]
(Cell-free assay)		 FGFR2 [1]
(Cell-free assay)		 FGFR3 [1]
(Cell-free assay)		 FGFR4 [1]
(Cell-free assay)
0.47 nM 0.6 nM 0.74 nM 3.5 nM
In vitro

ASP5878 inhibits the cell proliferation of HCC cell lines expressing FGF19. ASP5878 inhibits FGFR4 phosphorylation and its treatment results in the suppression of phosphorylation, mobility shift of FRS2, and suppression of ERK phosphorylation in Hep3B2.1-7 cells[1].
In vivo

Oral administration of ASP5878 at 3 mg/kg induces sustained tumor regression in a subcutaneous xenograft mouse model using Hep3B2.1-7. In HuH-7, an orthotopic xenograft mouse model, ASP5878 induces complete tumor regression and dramatically extended the survival of the mice[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    Hep3B2.1-7 cells

  • Concentrations

    0-1000 nM

  • Incubation Time

    2 h

  • Method

    --
Animal Study:

[1]
  • Animal Models

    HCC orthotopic xenograft model

  • Dosages

    3 mg/kg

  • Administration

    oral

Selleck's ASP5878 has been cited by 3 publications

Metabolic flexibility maintains proliferation and migration of FGFR signaling-deficient lymphatic endothelial cells [ J Biol Chem, 2021, S0021-9258(21)00950-9] PubMed: 34473994
FGFR Signaling Coordinates the Balance Between Glycolysis and Fatty Acid β-Oxidation in Lymphatic Endothelial Cells [ bioRxiv, 2020, 10.1101/2020.05.20.107326] PubMed: None
FGFR Signaling Coordinates the Balance Between Glycolysis and Fatty Acid β-Oxidation in Lymphatic Endothelial Cells [ bioRxiv, 2020, 10.1101/2020.05.20.107326] PubMed: N/A

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.